UPDATE 1-Novartis biosimilar takes aim at Amgen drug Neulasta

ZURICH, Nov 18 (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights infections in cancer patients, the Swiss group said on Wednesday.